STAAR Surgical Company (STAA) was Reiterated by The Benchmark Company to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 12 from a previous price target of $10 . The Benchmark Company advised their Clients and Investors in a research report released on Mar 3, 2017.
Based on several research reports , Company shares were Reiterated by The Benchmark Company on Mar 3, 2017 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .Company shares were Reiterated by The Benchmark Company on Mar 3, 2017 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10 .
On the company’s financial health, STAAR Surgical Company reported $0.02 EPS for the quarter, based on the information available during the earnings call on Mar 2, 2017. Analyst had a consensus estimate of $0.02. The company had revenue of $22.10 million for the quarter, compared to analysts expectations of $22.25 million. The company’s revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 EPS.
Several company insiders have filed Insider transactions , on Dec 9, 2016, Hans-martin Blickensdoerfer (Sr. VP, EMEA, LA and China) sold 25,000 shares at $11.21 per share price. According to the SEC, on May 23, 2016, Richard A Meier (director) sold 25,000 shares at $5.34 per share price. On Aug 26, 2015, Caren L Mason (CEO) purchased 10,000 shares at $7.34 per share price, according to the Form-4 filing with the securities and exchange commission.
STAAR Surgical Company (STAA) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $10.2 and reached the intraday high at $10.4. The bulls started the profit booking and pushed the shares to intraday low of $10.1. The trading session was marked by a volume range of 70,145 shares exchanging hands. The 52-week high of the shares is $11.5 and the 52-week low is $4.98. The market cap of the company stands at $412 M and there are 4,06,09,093 shares in public circulation.
STAAR Surgical Company designs develops manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company’s principal products are intraocular lenses (IOLs) and implantable Collamer lenses (ICLs). IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts and include the Company’s lines of silicone and Collamer IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). ICLs consisting of the Company’s ICL and Toric implantable collamer lenses (TICL) are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness) hyperopia (far-sightedness) and astigmatism. The Company operates under the brands STAAR Visian Collamer CentraFLOW AquaPORT nanoFLEX nanoPOINT Epiphany and AquaFlow. Collamer is the brand name for its collagen copolymer lens material.